PMID- 31907120
OWN - NLM
STAT- MEDLINE
DCOM- 20200923
LR  - 20200923
IS  - 0031-7144 (Print)
IS  - 0031-7144 (Linking)
VI  - 74
IP  - 12
DP  - 2019 Dec 1
TI  - Cost-effectiveness and safety of palbociclib and everolimus for treating advanced 
      and recurrent breast cancer.
PG  - 763-766
LID - 10.1691/ph.2019.9719 [doi]
AB  - This retrospective study compares the economic superiority of palbociclib versus 
      everolimus for advanced and recurrent breast cancer. Furthermore, we investigated 
      the safety and treatment continuity of palbociclib and everolimus regimens. 
      Expected costs were calculated based on data from patients with advanced and 
      recurrent breast cancer who were treated with palbociclib and everolimus. The 
      progression-free survival (PFS) from the PALOMA-3 clinical trial and BOLERO-2 
      clinical trial was used to evaluate the therapeutic efficacy of the regimens. The 
      cost-effectiveness ratio of each chemotherapy agent was calculated by dividing 
      the expected cost by the progression-free survival (PFS). The cost-effectiveness 
      ratio per month was JPY 391,551.3/PFS for palbociclib and JPY 488,690.5/PFS for 
      everolimus (p=0.627). The incremental cost-effectiveness ratio per month of 
      everolimus to palbociclib was JPY 100,133.7/PFS. For patients receiving 
      everolimus, adverse drug reactions included stomatitis (77.3%), rash (59.1%) and 
      leukopenia (59.1%). For patients receiving palbociclib, neutropenia (69.2%), 
      leukopenia (69.2%) and anemia (30.8%) occurred. In terms of discontinuation owing 
      to adverse events (AEs), pneumonitis, thrombocytopenia, edema, fatigue, and 
      neutropenia were experienced in the everolimus group. The cost-effectiveness of 
      everolimus and palbociclib are equivalent, but since the prevalence of AEs is 
      high in patients receiving everolimus, its AE management is important.
FAU - Kimura, M
AU  - Kimura M
FAU - Usami, E
AU  - Usami E
FAU - Yoshimura, T
AU  - Yoshimura T
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Pharmazie
JT  - Die Pharmazie
JID - 9800766
RN  - 0 (Piperazines)
RN  - 0 (Pyridines)
RN  - 9HW64Q8G6G (Everolimus)
RN  - G9ZF61LE7G (palbociclib)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Breast Neoplasms/*drug therapy
MH  - Everolimus/adverse effects/*economics/*therapeutic use
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/*drug therapy
MH  - Piperazines/adverse effects/*economics/*therapeutic use
MH  - Pyridines/adverse effects/*economics/*therapeutic use
EDAT- 2020/01/08 06:00
MHDA- 2020/09/24 06:00
CRDT- 2020/01/08 06:00
PHST- 2020/01/08 06:00 [entrez]
PHST- 2020/01/08 06:00 [pubmed]
PHST- 2020/09/24 06:00 [medline]
AID - 10.1691/ph.2019.9719 [doi]
PST - ppublish
SO  - Pharmazie. 2019 Dec 1;74(12):763-766. doi: 10.1691/ph.2019.9719.